Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19791984 | 0.83 | TSHR (0.47) | KDM4EPOLBTSHRCHRM3NAAA | |
| SCHEMBL26688783 | 0.83 | TSHR (0.47) | KDM4EPOLBTSHRCHRM3NAAA | |
| SCHEMBL5529079 | 0.83 | KDM4E (0.53) | KDM4EPOLBTSHRCHRM3CTSS | |
| SCHEMBL15679761 | 0.81 | TSHR (0.44) | KDM4EPOLBTSHRCHRM3NAAA | |
| SCHEMBL27363085 | 0.78 | TSHR (0.48) | KDM4EPOLBTSHRCHRM3NAAA | |
| SCHEMBL14477302 | 0.78 | DRD2 (0.46) | KDM4ETSHRSLC6A2TAAR1 | |
| SCHEMBL27894071 | 0.77 | BLM (0.46) | KDM4EPOLBTSHRL3MBTL1GHSR | |
| SCHEMBL6886009 | 0.77 | TSHR (0.56) | KDM4EPOLBTSHRNAAAL3MBTL1 | |
| SCHEMBL15663667 | 0.77 | TSHR (0.47) | KDM4EPOLBTSHRNAAASLC6A2 | |
| SCHEMBL31032489 | 0.76 | L3MBTL1 (0.46) | TSHRCHRM3NAAASGMS2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083917-A1 | Polycyclic Kinase Inhibitor | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2024-03-14 | — | — | US | disclosed |
| EP-4289853-A1 | POLYCYCLIC KINASE INHIBITOR | Shandong Xuanzhu Pharma Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116669741-A | Polycyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022148354-A1 | POLYCYCLIC KINASE INHIBITOR | 山东轩竹医药科技有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148354-A1 | POLYCYCLIC KINASE INHIBITOR | 山东轩竹医药科技有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20110190306-A1 | Inhibitors of PLK | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190306-A1 | Inhibitors of PLK | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190306-A1 | Inhibitors of PLK | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2296662-A1 | INHIBITORS OF PLK | Chroma Therapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009136144-A1 | PURINE DERIVATIVES SUITABLE FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | CHROMA THERAPEUTICS LTD (GB) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009130453-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130453-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | KDM4E 1651/4885POLB 3255/4885TSHR 2888/4885 |
| US-20110190306-A1 | Inhibitors of PLK | PLK3, PLK2, PLK4 | KDM4E 3619/4885POLB 931/4885TSHR 496/4885 |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | KDM4E 1651/4885POLB 3255/4885TSHR 2888/4885 |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | AADAC, TNNI3, TNNT2 | KDM4E 2228/4885POLB 2527/4885TSHR 2879/4885 |
| US-20240083917-A1 | Polycyclic Kinase Inhibitor | PRKDC, DCK, DMPK | KDM4E 944/4885POLB 286/4885TSHR 3961/4885 |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | KDM4E 1651/4885POLB 3255/4885TSHR 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.